13 January 2021

Rutherford Health plc

Rutherford Health - Agreement to provide services to NHS

Rutherford Health plc (the "Company" or "Group" or "Rutherford Health") announces that Rutherford Cancer Care Limited, its wholly owned subsidiary, has entered into a framework agreement with NHS England under which it will provide cancer treatment and diagnostic imaging services to NHS Trusts and clinical commissioning groups.

The agreement is for a two-year period with an option to extend for a further two years on the agreement of both parties. Services will be provided at a pre-agreed set of prices.

Mike Moran, CEO of Rutherford Health plc, commented: "We are absolutely delighted to have signed this agreement with NHS England. We have been supplying radiotherapy and systemic anti-cancer therapy to NHS patients in England and Wales. This agreement streamlines the procurement process and enables NHS organisations in England to commission a range of services directly from us. It means we will provide our services more widely.

"I am particularly pleased to be supporting the fantastic work that the NHS is doing at this extremely challenging time. Providing these much-needed cancer treatments and diagnostic services in dedicated cancer treatment facilities will help relieve pressure on NHS hospitals".

Information communicated within this announcement is deemed to constitute inside information as stipulated under the UK Market Abuse Regulation. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

The directors of Rutherford Health plc accept responsibility for the contents of this announcement.

VIEW ANNOUNCEMENT ON AQUIS